WEBINAR |  JANUARY, 13-15, 2021    

16th Residential Course
on Clinical Pharmacology
of Antiretrovirals


COURSE DIRECTOR

Giovanni Di Perri

Head of the Department of Infectious Diseases, University of Turin, Italy

COURSE SCIENTIFIC SECRETARY

Stefano Bonora

Department of Infectious Diseases, University of Turin, Italy

Phone + 39 011 4393980/4393867, Fax +39 011 4393882
E-mail stefano.bonora@unito.it

Andrea Calcagno

Department of Infectious Diseases, University of Turin, Italy

Phone + 39 011 4393980/4393867, Fax +39 011 4393882
E-mail andrea.calcagno@unito.it

DATES AND SCHEDULE

WEDNESDAY 13 JAN 2021

2:00 PM - 6:15 PM

THURSDAY 14 JAN 2021

9:00 AM - 7:15 PM

FRIDAY 15 JAN 2021

9:00 AM - 1:45 PM

COURSE RATIONALE

Rapid advances in disease management require the ongoing attention of healthcare professionals. This course will address the implications of new PK/PD information on strategies for clinical management of patients with HIV, HBV and HCV infections.
Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert panel of clinicians and researchers. The three-day course will bring together researchers and clinicians from various parts of the world to discuss pro and cons of current PK/PD strategies in anti-infective area. Each topic focus on preclinical, translational and clinical aspects and will provide opportunity for discussion and input from the audience. This meeting will be a valuable experience for all involved in infectious diseases, as researchers or prescribers of anti-infective agents.

LEARNING OBJECTIVES

Participants will be taught on learning goals:

  • Recognize the role of PK/PD parameters for the management of HIV, HBV and HCV infections.
  • Focus on recent developments regarding PK variability of antivirals and its association with specific tissue drug penetration and clearance.
  • Describe the challenges of HIV, HBV and HCV treatment as it relates to cure and selection of drug resistance.
  • Develop strategies to modify HIV and anti-hepatitis treatment regimens based on individual patient response.
  • Devise a plan to manage drug interactions and adverse effects of HIV, HBV and HCV treatments and optimize treatment responses.
  • Present real and typical clinical scenarios, discuss findings and management in the light of current PK/PD data and clinical practices guidelines.